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Abstract
We report the first genome-wide association study of habitual caffeine intake. We included 47,341 individuals of European
descent based on five population-based studies within the United States. In a meta-analysis adjusted for age, sex, smoking,
and eigenvectors of population variation, two loci achieved genome-wide significance: 7p21 (P=2.4610
219), near AHR, and
15q24 (P=5.2610
214), between CYP1A1 and CYP1A2. Both the AHR and CYP1A2 genes are biologically plausible candidates
as CYP1A2 metabolizes caffeine and AHR regulates CYP1A2.
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Caffeine (1,3,7-trimethylxanthine) is the most widely consumed
psychoactive substance in the world with nearly 90% of adults
reporting regular consumption of caffeine-containing beverages
and foods [1,2]. Although demographic and social factors have
been linked to habitual caffeine consumption, twin studies report
heritability estimates between 43 and 58% for caffeine use; 77%
for heavy use, and 45, 40, and 35%, respectively, for caffeine
toxicity, tolerance and withdrawal symptoms [3]. Genetic
association studies focused on candidate genes related to the
pharmacokinetic and pharmacodynamic properties of caffeine
have identified genes encoding cytochrome P-450 (CYP)1A2, as
the primary enzyme involved in caffeine metabolism [3,4]. The
genome-wide association approach has emerged as a powerful
means for discovering novel loci related to habitual use of a second
stimulant, tobacco [5], but has not yet clearly identified genes for
other common behavioral traits, including caffeine consumption.
To comprehensively examine the influence of common genetic
variation on habitual caffeine consumption behavior we undertook
a meta-analysis of genome-wide association studies (GWAS) from
population-based cohorts. Our study confirms the important roles
of CYP1A2 and AHR in determining caffeine intake, thus
supporting the utility of the GWAS approach to the discovery of
loci linked to this complex behavioral trait.
Results
We performed a meta-analysis of 47,341 individuals of
European descent, derived from five studies within the US, the
Atherosclerosis Risk in Communities (ARIC, N=8,945) Study,
the Prostate, Lung, Colorectal, and Ovarian Cancer Screening
Trial (PLCO, N=4,942), the Nurses’ Health Study (NHS,
N=6,774), the Health Professionals Follow-Up Study (HPFS,
N=4,023), and the Women’s Genome Health Study (WGHS,
N=22,658). Sample characteristics are presented in Table 1.
Caffeine intake was assessed using semi-quantitative food frequen-
cy questionnaires (FFQ) that included questions on the consump-
tion of caffeinated coffee, tea, soft drinks, and chocolate.
Study-level genomic inflation factors (l) were low ranging from
1.00 (PLCO) to 1.03 (HPFS), suggesting that population
stratification was well controlled (Figure S1). A total of 433,781
imputed and genotyped SNPs passed our stringent criteria for the
meta-analysis. Test statistic inflation at the meta-analysis level
revealed no evidence of notable underlying population substruc-
ture (l=1.04, Figure 1).
Two loci reached genome-wide significance with no evidence for
significant between- study heterogeneity (Table 2, Figure 2 and
Figure 3, Table S1). The strongest associated SNP (rs4410790,
P=2.4610
219, Figure S2) is located at 7p21, 54 kb upstream of
AHR (aryl hydrocarbon receptor). The second strongest associated
SNP (rs2470893, P=5.2610
214, Figure S2) mapped to 15q24
within the bidirectional promoter of the CYP1A1-CYP1A2 locus
[6,7]. A synonymous coding SNP (rs2472304, P=2.5610
27)i n
CYP1A2exon7thatwashighlycorrelated with6otherSNPsbutnot
correlated with rs2470893 (r
2=0.18, HapMap CEU) was amongst
the highest ranked loci in our meta-analysis (Table 2). Although we
only considered variants that were imputed with high probability,
Table 1. Descriptive characteristics of studies participating in meta-analysis.*
Study Description N Female, % Age, years Caffeine, mg/day Current smokers, % Platform
ARIC Cohort 8,945 52.8 54.3 (5.7) 332.9 (311.1) 24.4 Affymetrix 6.0
PLCO Cohort: nested case-control** 4,942 23.5 67.7 (5.4) 491.1 (494.1) 22.1 Illumina 240K
Illumina 310K
Illumina 550k
Illumina 610Q
NHS T2D Cohort: nested T2D case-control 3,135 100 51.1 (10.5) 284.5 (206.3) 14.8 Affymetrix 6.0
NHS CHD Cohort: nested CHD case-control 1,102 100 53.5(10.6) 316.7 (218.0) 30.0 Affymetrix 6.0
NHS KS Cohort: nested KS case-control 488 100 47.7 (11.7) 264.4 (203.6) 15.3 Illumina 610Q
NHS BrC Cohort: nested BrC case-control 2,049 100 52.3 (9.6) 286.5 (204.0) 15.6 Illumina 550k
HPFS T2D Cohort: nested T2D case-control 2,381 0 55.5 (8.4) 250.9 (227.6) 7.6 Affymetrix 6.0
HPFS CHD Cohort: nested CHD case-control 1,099 0 56.7 (8.7) 243.2 (230.7) 9.9 Affymetrix 6.0
HPFS KS Cohort: nested KS case-control 543 0 48.8 (6.8) 230.5 (241.6) 6.4 Illumina 610Q
WGHS Cohort 22,658 100 54.7 (7.1) 298.5 (232.9) 11.5 Illumina HumanHap300
Duo+
Total 47,341
*Values are mean (standard deviation) for age and caffeine; percent for female and current smokers.
**Includes samples from prostate cancer case-control (n=1885), bladder cancer case-control (n=572), glioma case-control (n=3), lung cancer case-control (n=1758),
pancreatic cancer case-control (n=299), renal cancer case-control study (n=271).
doi:10.1371/journal.pgen.1002033.t001
Author Summary
Caffeine is the most widely consumed psychoactive
substance in the world. Although demographic and social
factors have been linked to habitual caffeine consumption,
twin studies report a large heritable component. Through
a comprehensive search of the human genome involving
over 40,000 participants, we discovered two loci associated
with habitual caffeine consumption: the first near AHR and
the second between CYP1A1 and CYP1A2. Both the AHR
and CYP1A2 genes are biologically plausible candidates, as
CYP1A2 metabolizes caffeine and AHR regulates CYP1A2.
Caffeine intake has been associated with manifold
physiologic effects and both detrimental and beneficial
health outcomes. Knowledge of the genetic determinants
of caffeine intake may provide insight into underlying
mechanisms and may provide ways to study the potential
health effects of caffeine more comprehensively.
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individuals with genotyped data (Table 2). Regression coefficients
remained essentially unchanged, but P-values were less significant
reflecting the reduced sample size (rs4410790: P=4.0610
218;
rs2470893 P=9.5610
28). Similar results were also observed when
men and women were examined separately (Table S2). Had the
analysis been performed instead by discovery at genome-wide
significance (P,5610
28) in the WGHS followed by replication in
meta-analysis of the remaining cohorts, only SNPs at the same loci
would have met Bonferroni corrected standards of significance. In a
post-hoc investigation of study heterogeneity in which we compared
WGHS to the remaining studies combined, there was significant
heterogeneity for rs4410790 (P=0.01), although this could be
attributable to chance.
Based on the well-established biological link between smoking
and AHR [8], and CYP1A2 [9] and caffeine consumption behavior
[2], we explored the role of cigarette smoking (Table 3). Compared
to our primary model that adjusted for smoking, a model not
adjusted for smoking yielded slightly attenuated associations and
when restricting analyses to ‘never smokers’ similar regression
coefficients were observed as for the complete study population.
These findings suggest that smoking is unlikely the cause of the
associations observed in our GWAS of caffeine intake.
We further conducted 21 candidate gene analyses and found
significant gene-based associations (Bonferroni corrected for the
total number of human genes) between CYP2C9 (P=0.023), and
ADORA2A (P=0.011) and caffeine intake in addition to CYP1A2
and AHR (Table 4).
Discussion
In the first GWAS of caffeine intake in a total of 47,341
individuals from five U.S. studies, loci at 15q24 and 7p21 achieved
genome-wide significance. CYP1A2 at 15q24 and AHR at 7p21 are
attractive candidate genes for caffeine intake. At plasma
concentrations typical of humans (,100 mM), caffeine is predom-
inantly (,95% of a dose) metabolized by CYP1A2 via N
1-, N
3-,
and N
7-demethylation to its three dimethylxanthines, namely,
theobromine, paraxanthine, and theophylline, respectively [10].
CYP1A2 expression and activity vary 10- to 60-fold between
individuals [11]. Human CYP1A2 is located immediately adjacent
to CYP1A1 in reverse orientation and the two genes share a
common 59-flanking region [12]. At least 15 AHR response
elements (AHRE) reside in this bidirectional promoter region and
rs2470893 is located in AHRE6 (originally reported as AHRE5[7])
which correlates with transcriptional activation of both CYP1A1
and CYP1A2 [6,7]. CYP1A1 expression in the liver (the target tissue
for caffeine metabolism) is low and there is little evidence that this
enzyme contributes to caffeine metabolism. This contrasts with the
tissue specific expression of CYP1A2 in the liver, which suggests
Figure 1. QQ plot for the genome-wide meta-analysis of caffeine consumption.
doi:10.1371/journal.pgen.1002033.g001
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observation that a stronger association exists for SNPs upstream of
the gene suggests that variation in CYP1A2 gene expression
probably affects caffeine intake. The protein product of AHR,
AhR, is a ligand–activated transcription factor that, upon binding,
partners with ARNT and translocates to the nucleus where it
regulates the expression of a number of genes including CYP1A1
and CYP1A2. There is marked variation in AhR binding affinity
across populations, but so far no polymorphisms have been
identified that account for this variation [13]. The most studied
SNP, rs2066853 (R554K), is located in exon 10, a region of AHR
that encodes the transactivation domain[13]. Although this SNP
was associated with caffeine in the current study (P=0.0004), our
strongest signal mapped upstream of AHR, suggesting variation in
AHR expression has a key role in propensity to consume caffeine.
An interaction between CYP1A2 and AHR could be biologically
plausible; however, we did not find any evidence supporting
statistical interaction between the top two loci (data not shown).
Human and animal candidate gene studies for caffeine intake
and related traits have focused on various other genes linked to
caffeine’s metabolism and targets of action. In our candidate gene
analyses, we observed significant gene-based associations between
CYP2C9 and ADORA2A and caffeine intake in addition to CYP1A2
and AHR. CYP2C9 catalyzes the N
7-demethylation and C
8-
hydroxylation of caffeine to theophylline and 1,3,7-trimethyluric
acid (a minor metabolite), respectively; but its role relative to
CYP1A2 is generally small [10]. In amounts typically consumed
from dietary sources, caffeine antagonizes the actions of adenosine
at the adenosine A2A receptor (ADORA2A) [2], which plays an
important role in the stimulating and reinforcing properties of
caffeine [14,15]. Polymorphisms of ADORA2A have been previ-
ously implicated in caffeine-induced anxiety as well as habitual
caffeine intake [16,17].
All studies contributing to our GWAS of caffeine intake were US-
based. Consistent with the adult caffeine consumption pattern of
this country, coffee contributed to well over 80% of caffeine intake.
Previous studies suggest that some of the heritability underling
specific caffeine sources (i.e. coffee and tea) may be distinct in
relation to total caffeine intake [18]. To evaluate the robustness of
findings, we conducted an additional GWAS analysis using
caffeinated coffee intake as the outcome variable yielding the same
strong signals (rs4410790: 1.4610
229, rs2470893: 3.6610
219).
Imprecision in phenotypic assessment and differences across
studies could have limited the scope of our discovery. Although
dietary intake obtained by FFQ is subject to misclassification,
validation studies in subsamples of the included studies indicated
that the consumption of caffeine-containing beverages is assessed
with good accuracy [19,20,21]. The cubic root transformation we
applied to reported caffeine intakes, however, limits interpretation
of the effect estimates. The crude weighted mean difference in
caffeine intake between homozygote genotypes was 44 mg/d for
rs4410790 and 38 mg/d for rs2470893 (Table S3 and S4). The
two SNPs together, however, explained between 0.06 and 0.72%
of the total variation in caffeine intake across studies suggesting
additional variants remain to be discovered [22]. Finally, our
GWAS assumed an additive genetic model and based on study-
level results (Figure 1 and Figure 2) potential non-linear effects will
require confirmation in future studies.
Caffeine intake has been associated with pleotropic physiologic
effects in relation to both detrimental and beneficial health
outcomes [23]. Our current study provides insights into the
primary pathways underlying caffeine intake. Knowledge of the
genetic determinants of caffeine intake may provide insight into
underlying mechanisms and may provide ways to study the
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genetic determinants as instrumental variables for caffeine intake
or by taking into consideration caffeine-gene interactions. With the
exception of nicotine dependency and the associated nicotinic
receptor, genes that influence traits associated with dependency
have been difficult to identify. The association of caffeine
consumption with genes involved in metabolism or its regulation
(CYP1A2 and AhR, respectively) illustrates that it is feasible to use
GWAS to identify genetic determinants of other behavioral traits
that are assessed with lower accuracy. We also recognize that the
identified variants could influence regulation of their genomic
elements distant from the known, high profile, neighboring
candidate genes. In conclusion, we identified two loci related to
caffeine consumption that will be worthy of further investigation
with regard to both beneficial and toxic effects of caffeine as well as
the extensive group of carcinogens, drugs, and xenobiotics also
metabolized through action of the regulation of the gene products
of CYP1A2 and AHR.
Material and Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. All participants in the contributing
studies gave written informed consent including consent for
genetic analyses. Local institutional review boards approved study
protocols.
Study Populations
We conducted a meta-analysis of 47,341 individuals of
European descent, sourced from Atherosclerosis Risk in Commu-
nities (ARIC, N=8,976), the Prostate, Lung, Colorectal, and
Ovarian Cancer Screening Trial (PLCO, N=4,942), the Nurses’
Health Study (NHS, N=6,774), the Health Professionals Follow-
Up Study (HPFS, N=4,023), and the Women’s Genome Health
Study (WGHS, N=22,658) to identify novel loci associated with
habitual caffeine consumption. Study population descriptions and
genotyping quality control for data generated with either the
Affymetrix 6.0 or the Illumina Infinium arrays (HumanHap300,
550 or 610 arrays) are provided in Text S1 and Table S5 and S6.
Caffeine Intake Assessment
In the NHS, every 2 to 4 years of follow-up diet was assessed
using a validated semi-quantitative food frequency questionnaire
(FFQ) [24]. For the present analysis, we included the participants’
mean caffeine intakes of the 1984 (first year in which caffeinated
and decaffeinated coffee were differentiated) and 1986 FFQs. The
following caffeine-containing foods and beverages were included
in the FFQ: coffee with caffeine, tea, cola and other carbonated
Figure 2. The –log10 P-plots for the genome-wide meta-analysis of caffeine consumption.
doi:10.1371/journal.pgen.1002033.g002
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PLoS Genetics | www.plosgenetics.org 5 April 2011 | Volume 7 | Issue 4 | e1002033beverages with caffeine, and chocolate. For each item, participants
were asked how often, on average, they had consumed a specified
amount of each beverage or food over the past year. The
participants could choose from nine frequency categories (never,
1–3 per month, 1 per week, 2–4 per week, 5–6 per week, 1 per
day, 2–3 per day, 4–5 per day and 6 or more per day). Intakes of
nutrients and caffeine were calculated using US Department of
Agriculture food composition sources. In these calculations, we
assumed that the content of caffeine was 137 mg per cup of coffee,
47 mg per cup of tea, 46 mg per can or bottle of cola or other
caffeinated carbonated beverage, and 7 mg per 1 oz serving of
chocolate candy. We assessed the total intake of caffeine by
summing the caffeine content for the specified amount of each
food multiplied by a weight proportional to the frequency of its
use. In a validation among a subsample of this cohort, we obtained
high correlations between intake of caffeinated coffee and other
caffeinated beverages from the FFQ and four 1-week diet records
(coffee, r=0.78; tea, r=0.93; and caffeinated sodas, r=0.85) [21].
In the WGHS, caffeine intake was assessed at baseline (1991)
using the same FFQ and caffeine algorithm as the NHS [25].
HPFS participants have been followed with repeated FFQs
every 4 years. Caffeine-intake was assessed by the same methods as
described above for the NHS cohort. In a validation study in a
subsample of participants, we obtained high correlations between
consumption of coffee and other caffeinated beverages estimated
from the FFQ and consumption estimated from repeated 1-wk diet
records (coffee: r=0.83; tea: r=0.62; low-calorie caffeinated
sodas: r=0.67; and regular caffeinated sodas: r=0.56)[21]. For
the present analysis, we included the participants mean caffeine
intakes of the 1986 (baseline) and 1990 FFQs.
In the ARIC study, caffeine consumption was quantified at the
baseline (1987–1989) examination from an interview-administered
Figure 3. Forest plots of the meta-analysis for the two caffeine-associated loci. A) rs4410790 and B) rs2470893. The contributing effect
from each study is shown by a square, with confidence intervals indicated by horizontal lines. The contributing weight of each study to the meta-
analysis is indicated by the size of the square. The meta-analysis estimate is shown at the bottom of each graph.
doi:10.1371/journal.pgen.1002033.g003
Table 3. Genome-wide meta-analysis of caffeine consumption (P,10
26): Smoking effects.
Index SNP Chr EA Not Adjusted for Smoking Never Smokers Current Smokers
N b PP het*N b PP het*N b PP het*
rs4410790 7 T 36150 20.15 8.2610
218 0.18 16809 20.19 1.8610
214 0.09 5058 20.10 0.02 0.96
rs2470893 15 T 47612 0.12 5.0610
213 0.70 21413 0.13 3.0610
28 0.19 7466 0.06 0.16 0.56
rs2472304 15 A 47596 0.07 2.4610
26 0.15 21410 0.07 0.0019 0.03 7464 0.03 0.36 0.47
rs6495122 15 A 47612 20.07 5.2610
26 0.24 21413 20.07 0.0011 0.03 7466 20.01 0.75 0.38
rs12148488 15 T 47612 20.07 1.9610
26 0.63 21413 20.08 0.0001 0.07 7466 20.002 0.97 0.27
Chr, chromosome; EA, effect allele;
*P value for between study heterogeneity.
doi:10.1371/journal.pgen.1002033.t003
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Database was used to assign caffeine (and nutrient) content to each
of the food and beverage line items. Line items quantifying
consumption of caffeine-containing beverages included sodas
(regular and diet), coffee, and tea. The frequency of consumption
of each of these items was multiplied by their caffeine content and
summed across all beverages to obtain a total caffeine intake value.
Caffeine intake in the PLCO trial was assessed at the
randomization phase (between 1992–2001) using responses from
a FFQ developed at the National Cancer Institute called the Diet
History Questionnaire (DHQ). The DHQ was previously
validated against four 24 hour dietary recalls [26] and asks about
consumption frequency of 124 food items over the past 12 months,
including the primary sources of caffeine: coffee, tea, and soft
drinks. For soft drinks, participants selected among 10 possible
frequency response categories from ‘‘never’’ to ‘‘6+ times per day,’’
with three possible portion size response categories: ,12 ounces or
,1 can or bottle; 12–16 ounces or 1 can or bottle; or .16 ounces
or .1 can or bottle. Frequency and portion size for coffee and tea
were queried together as cups per unit time ranging from ‘‘none’’
to ‘‘6 or more cups per day.’’ For all three of the above beverages,
participants were asked the proportion of the time each were
consumed in decaffeinated form (almost never or never, about J
of the time, about K the time, about L of the time, almost always
or always). From these responses daily consumption of caffeine was
computed taking into account the caffeine content, portion size,
and frequency of intake. Caffeine estimates were derived from two
24-hour dietary recalls administered in the 1994-96 Continuing
Survey of Food Intake by Individuals (CSFII)[27], a nationally
representative survey conducted during the period when the DHQ
was being administered. Individual foods/beverages reported on
the recalls were placed in food groups consistent with items on the
DHQ and weighted mean nutrient values based on survey data
were derived for adults stratified by sex using methods previously
described [28].
Imputation
Each study used either MACH [29] (ARIC, NHS, HPFS,
WGHS) or IMPUTE [30] (PLCO) to impute up to ,2.5 million
autosomal SNPs with NCBI build 36 of Phase II HapMap CEU
data (release 22) as the reference panel. Genotypes were imputed
for SNPs not present in the genome-wide arrays or for those where
genotyping had failed to meet the quality control criteria.
Imputation results are summarized as an ‘‘allele dosage’’ (a
fractional value between 0 and 2), defined as the expected number
of copies of the minor allele at that SNP.
Phenotype Harmonization and Model Selection
The algorithm used for the calculation of caffeine intake was
study-specific to allow for differences in questionnaires and
consumption habits in different study populations. Raw caffeine-
intake measures were skewed across studies and after exploring a
variety of transformation options, we found that a cubic-root
transformation was very close to the most optimal transformation
identified by the Box-Cox procedure and was used to ensure
normality of the residuals. Our final models were also adjusted for
Table 4. Candidate gene-based association results.*
Chr Gene #SNPs #simulations start position stop position Gene-based P
1 ADORA3 43 1000 111827492 111908120 0.69
1 FMO3 26 1000 169326659 169353583 0.17
1 ADORA1 43 1000 201363458 201403156 0.13
2 XDH 47 1000 31410691 31491115 0.22
5 DRD1 33 100000 174800280 174803769 0.10
7 AHR 18 1000000 17304831 17352299 ,1610
26
7 CYP3A4 11 1000 99192539 99219744 0.56
7 CYP3A43 3 1000 99263571 99302109 0.58
8 NAT1 3 1000 18111894 18125100 0.52
8 NAT2 32 1000 18293034 18303003 0.62
10 CYP2C9 23 100000 96688404 96739138 0.023
10 CYP2C8 20 100000 96786518 96819244 0.05
10 CYP2E1 16 1000 135190856 135202610 0.23
11 DRD2 34 100000 112785526 112851211 0.077
12 TAS2R7 4 1000 10845397 10846493 0.96
12 TAS2R14 1 1000 10982119 10983073 0.72
15 CYP1A2 11 1000000 72828236 72835994 ,1610
26
17 ADORA2B 15 1000 15788955 15819935 0.30
17 PPP1R1B 19 1000 35036704 35046404 0.74
19 CYP2A6 45 1000 46041282 46048192 0.43
19 CYP2A7 28 1000 46073183 46080497 0.60
22 COMT 41 1000 18309308 18336530 0.27
22 ADORA2A 8 100000 23153529 23168325 0.011
*Gene-based analyses were performed using VEGAS [37]. See Materials and Methods for details.
doi:10.1371/journal.pgen.1002033.t004
Genome-Wide Association Study of Caffeine Intake
PLoS Genetics | www.plosgenetics.org 7 April 2011 | Volume 7 | Issue 4 | e1002033age (continuous), sex, case-control status (if applicable), study-site
(if applicable), smoking status (never, former, and current: 2
categories), and study specific eigenvectors (see Table S5 for study-
specific models). Adjustment for smoking status was appropriate
given the strong correlation between smoking and caffeine intake
that might impede our ability to uncover caffeine-specific loci.
Each study collected information on smoking status at the time
FFQ were administered. A flexible modeling approach was used to
accommodate the different methods by which smoking was
collected across studies, but all included never, former and two
categories of current smokers. Further adjustments for body-mass-
index did not change results appreciably.
Study-Level GWAS
Each study performed genome-wide association testing for
normalized caffeine-intake across ,2.5 million SNPs, based on
linear regression under an additive genetic model. Analyses were
adjusted for additional covariates as described above and further
detailed in Table S5. Imputed data (expressed as allele dosage)
were examined using ProbABEL[31] or R (scripts developed in-
house). The genomic inflation factor l for each study as well as the
meta-analysis was estimated from the median x
2 statistic.
Meta-Analysis
Meta-analysis was conducted using a fixed effects model and
inverse-variance weighting as implemented in METAL (see URLs
in Text S1). The software also calculates the genomic control
parameter and adjusts each study’s standard errors. Fixed effects
analyses are regarded as the most efficient method for discovery in
the GWAS setting [32]. Heterogeneity across studies was
investigated using the I
2 statistic[33]. We applied stringent quality
filters to imputed SNPs prior to meta-analysis; removing those
with ,0.02 MAF and/or with low imputation quality scores. The
latter was defined as Rsq#0.80 for SNPs imputed with MACH
and proper_info#0.7 for SNPs imputed with IMPUTE. X and Y
chromosome, pseudosomal and mitochondrial SNPs were not
included for the present analysis. We retained only SNP-
phenotype associations that were based on results from at least 2
of the 10 participating studies and if greater than 50% of the
samples contributing to the results were genotyped. Additional
checks for experimental biases were implemented for notable
associations including manual inspection of SNP (if imputed, an
assayed SNP in high LD) cluster plots, and evaluation of HWE,
and comparison of study MAFs to the HapMap CEPH panel. We
considered P-values ,5610
28 to indicate genome-wide signifi-
cance [34].
Candidate Gene–Based Analyses
We examined 515 SNPs in 23 genes (650 kb) either previously
studied or members of the key biological pathway: ‘Caffeine
metabolism’ (KEGG [35], supplemented with candidates
from[10,36]) for association with caffeine consumption in our
GWA meta-analysis sample. SNPs mapping to TAS2R10, 43 and
46, implicated in the oral detection of caffeine, did not pass our
stringent QC criteria and thus were not included. Gene-based
analyses were performed using VEGAS [37]. The software applies
a test that incorporates information from a set of markers within a
gene (or region) and accounts for LD between markers by using
simulations from the multivariate normal distribution. The
number of simulations per gene is determined adaptively. In the
first stage, 1000 simulations are performed. If the resulting
empirical P value is less than 0.1, 10000 simulations are
performed. If the empirical P value from 10000 simulations is
less than 0.0001, the program will perform 1000000 simulations.
At each stage, the simulations are mutually exclusive. For
computational reasons, if the empirical P value is 0, then no
more simulations will be performed. An empirical P value of 0
from 1000000 simulations can be interpreted as P,10 E-6, which
exceeds a Bonferroni-corrected threshold of P,2.8E-6 [,0.05/
17,787 (number of autosomal genes)].
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